v3.26.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development, net of grants $ 18,126 $ 15,745
General and administrative, net of grants 9,430 8,932
Total operating expenses 27,556 24,677
Loss from operations (27,556) (24,677)
Other income, net 947 1,191
Net loss $ (26,609) $ (23,486)
Net loss per common share - basic (in dollars per share) $ (0.43) $ (0.43)
Net loss per common share - diluted (in dollars per share) $ (0.43) $ (0.43)
Weighted average shares outstanding - basic (in shares) 62,389 54,981
Weighted average shares outstanding - diluted (in shares) 62,389 54,981

Source